U.S. markets open in 8 hours 12 minutes

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.6400+0.2300 (+6.74%)
At close: 04:00PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • C
    Yahoo! has been so bad lately - especially the ACIU board. I like using ( now instead for my daily research.
  • h
    Anyone else read ( Just got a tip about ACIU from them.
  • R
    If the upcoming presentation at this A D conference indicate positive results in any one of its multiple programs, share price can easily triple which is hardly the high of the year! We’ll see. This is the most well-financed small biotech with the largest programs in this particular sector. The potential is so high as indicated so many large pharmas have develop programs with this one.
  • g
    Thanks, I'll check them out.Thanks for the tip!Thanks for the update!
  • A
    Ah Lek

    Dundee Corp. portfolio holding TauRx Pharmaceuticals Ltd. unveiled initial data from the randomized portion of its widely followed phase 3 clinical trial, Lucidity (NCT03446001). Dundee holds 1,015,008 shares in TauRx.

    TauRx announcement highlights:

    Lucidity data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research.
    Safety profile is favourable and consistent with previous HMTM studies.
    TauRx will now pursue regulatory submission and coverage for HMTM.

    TauRx reports its lead investigative oral drug, HMTM, was tested in 598 people afflicted with Alzheimer's. TauRx announced participants of the 12-month blinded phase of the study have moved to an additional one-year open label phase.

    According to TauRx's announcement, Prof. Claude Wischik, executive chairman and co-founder of TauRx, commented: "The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer's based on published research. This was seen for both cognitive and functional end points across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer's. Importantly, the safety profile is favourable and consistent with previous studies."

    TauRx advises its data analysis is continuing and will be reported at a later date. Meanwhile, TauRx will be providing an update on their progress at the 35th Global Conference of Alzheimer's Disease on June 9, 2022.
  • P
    Any comment on ACIU? Is it a buy at this price?
  • B
    (ACOGF) $0.47 ---Alzheimer treatment with PHASE 3 data coming THIS month --$10+ BILLION market / under radar gem = 1000%++ OPP guys

  • A
    Does not look good.
  • W
    AC Immune - Pioneering precision medicine for neurodegenerative diseases

    1. Significant market potential for Alzheimer's disease (AD) and other neurodegenerative diseases
    >>> Broadest pipeline in the field addressing Tau, Abeta, a-syn, TDP-43 and neuro inflammation

    2. Highly differentiated precision medicine approach
    >>> Dual clinically validated platforms generate First/Best-in-Class therapeutics and diagnostics

    3. Most comprehensive portfolio of candidates targeting Tau at key points in disease pathway
    >>> Clinical-stage antibody, vaccine, small molecule inhibitor and diagnostic imaging agent

    4. Multiple clinical catalysts anticipated in 2020 to drive near term value inflection
    >>> Key upcoming data readouts: Abeta vaccine (Phase 1b, DS and Phase 2, AD);
    Tau small molecule (Phase 1); Tau PET tracer (Phase 1, PSP)

    5. Marquis partnerships with leading global pharma companies
    >>> Secured CHF 334 million to date in non-dilutive funding with >CHF 3 billion in potential
    milestone payments plus royalties

    6. Experienced management with strong tract record of developing and out-licensing assets
  • n
    Excellent forecast : Prof. Pfeifer continued, “We anticipate multiple catalysts in 2019 and 2020, highlighted by expected Phase 2 data for semorinemab, our anti-Tau antibody partnered with Genentech/Roche, which we anticipate will be the first Phase 2 data available for a Tau-targeted therapy in Alzheimer’s disease (AD). We also anticipate achieving further progress across our development pipeline with both early and late stage data readouts that we believe will build substantial value for the Company.”
  • B
    Biotechinvest Net
    BTW, when Biogen tested anti-tau Ab in Ad they failed:
    "Gosuranemab did not meet its primary efficacy endpoint of change from baseline at week 78 on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) compared to placebo in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease dementia. No treatment benefit was seen on exploratory efficacy endpoints, including the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog 13), the Alzheimer Disease Cooperative Study Activity of Daily Living (ADCS-ADL), the Mini-Mental State Examination (MMSE) and the Functional Assessment Questionnaire (FAQ). Gosuranemab was well-tolerated overall, and safety outcomes were consistent with previous studies of the molecule.
    Gosuranemab is an antibody directed against the N-terminus of tau. Target engagement was demonstrated with lowering of N-terminal tau in cerebrospinal fluid (CSF), consistent with prior studies. However, in the TANGO Study, no statistically significant treatment effect was observed on tau-PET at week 78 for any of the dose groups."
    Why Biogen Ab failed? Most likely that they targeted different epitope in N-terminus of tau. ACIU just choose correct epitope and got very good results.
  • C
    AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors

    Dr. Colowick has more than 20 years of experience in large and emerging biotech companies

    Led investments for several clinical-stage companies as a Partner at Sofinnova Investments

    LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Alan Colowick, MD, MPH, a deeply experienced biotech and investment executive, was elected to the Company's Board of Directors at an extraordinary shareholders' meeting today.

    Dr Colowick has more than 20 years of industry experience in both large and emerging biotech companies, serving in a broad array of board, senior executive, clinical, regulatory, and commercial positions. He has a deep understanding of value creation and growth strategies, serving as a Partner at Sofinnova Investments, where he led investments for several clinical-stage companies.

    Douglas Williams, Ph.D., Chairman of AC Immune SA, commented: "The wealth of experience and credibility Dr. Colowick brings to AC Immune's Board will be invaluable as we continue to execute on our corporate strategy and reinforce our scientific leadership in the field of neurodegenerative diseases. His extensive expertise in biotech from both industry and investment standpoints -- including from Celgene, Amgen and Sofinnova -- will bring an important perspective to our pipeline and corporate development. We are thrilled to welcome him as our newest Director."

    Dr. Colowick commented: "I am delighted to be elected to the Board of Directors at what is a particularly exciting moment for AC Immune. By pioneering a personalized medicine approach that properly recognizes the complexity of neurodegenerative disease, the Company has positioned itself at the forefront of the field, poised for sustained growth. I look forward to working with my new colleagues as we continue to advance one of the industry's broadest and most diversified pipelines in neurodegeneration."

    Prior to his time at Sofinnova, Dr. Colowick was Executive Vice President and served in various leadership roles at Celgene Corporation, including as President for Celgene's Europe, Mid-East, and Africa regions and as Senior Vice President of Global Medical Affairs. Before joining Celgene, he was the Chief Executive Officer at Gloucester Pharmaceuticals, Inc. where he led a private round of financing prior to the company's acquisition by Celgene in 2010. Dr. Colowick has also served as the President of Oncology at Geron Corporation, as Chief Medical Officer of Threshold Pharmaceuticals, and in numerous positions of increasing responsibility at Amgen culminating with his role as VP, Medical Affairs Europe.

    Dr. Colowick also has extensive Board experience that includes current roles on the Board of Directors for Personalis, Inc., XyloCor Therapeutics, and InCarda Therapeutics, and prior roles as Chairman of the Board including VelosBio (sold to Merck in 2020 for $2.75 billion) and Principia Biopharma (sold to Sanofi in 2020 for $3.7 billion). He received his medical degree from Stanford University, a Master's in Public Health from Harvard University, and a B.S. in Molecular Biology from the University of Colorado. Additionally, Dr. Colowick has completed specialty training in Hematology-Oncology at Harvard Medical School, the Dana Farber Cancer Institute, and Brigham and Women's Hospital in Boston, USA.

    Prior to the meeting, the Board withdrew agenda item 2.
  • J
    I don't understand it. Look at SAVA, it's got only 9 employees and came out with similar news, the stock jumped more than 200% and now has a market cap of almost 2B.

    ACIU has more than 100 employees and with the good news the stock is actually down from premarket?
  • c
    Difference in the run up with SAVA vs AC - SAVA started around $100MC while AC started at $500MC. And SAVA has a much lower share float making supply/demand effect more explosive. Biggest point is that SAVA reported cognitive improvement which is much more important than saying antibodies were present. Big difference. AC didn’t provide any statistical results which is more of a pump at the moment. I like AC and hold shares. I think they will get there and do have a much deeper pipeline of products than SAVA but what I’ve said above is exactly why u cannot compare this to SAVA’s current run up. Another really big deal too is that SAVA still holds all the rights to their drug so the possibility of a partnership adds even more value. AC is handcuffed to J&J- if their drug is successful, revenue is already defined by the rights agreement. They will get milestones and capped royalties. Hope I’m wrong and someone can explain differently.
  • W
    ACIU is way a lot to offer than SAVA. LOOK AT THE PIPELINE PEOPLE!!!
    Partners: Eli Lilly, Janssen ( a Johnson&Johnson Co.), Regeneron (a Roche Co. )
    ACIU and partners are way ahead in clinical studies than SAVA
  • j
    ACIU is undervalued and should be $18 suggested by Analysts. Planning ACI-35.030 into Phase 2/3 clinical trials on the way should rise above $30 soon. Not selling 1 share under $30 Buy more and hold.
  • #
  • B
    Biotechinvest Net
    If you have $8k and want 10x gain - just buy 1000 shares of ACIU. There are no so many biotechs that have real AD drugs in their portfolios and ACIU is definitely one of them. Why not SAVA? This is scam biotech with completely fake AD drug. Company founders will make big money and all investors will lose them. It will be the same story as AXON scam with its fake AD drug. So, if you want lose all your money just buy SAVA and after Ph3 AD results you will lose >95%.
    Why ACIU AD treatment is not a fake? Because p-tau is a main players in AD etiology - tau aggregates from dead neurons spreads through the brain and healthy neurons swallows them. Inside of healthy neurons defect tau starts to convert normal tau to aggregates. The mechanisms are similar to prion disease. Anti-p-tau antibodies should stop spread of pathogenic p-tau filaments through the brain and stop/slow down AD.
    What is SAVA filamin A (FLNA)? This protein never was known as AD player. SAVA founders just published several papers that showed that this protein can play some role in AD. But most likely these papers were fake results. If you open Wiki and ask about filamin A (FLNA) you will know that:
    "Filamins are a class of proteins that hold two actin filaments at large angles.[1] Filamin protein in mammals is made up of an actin-binding domain at its N-terminus that is followed by 24 immunoglobulin-like repeat modules of roughly 95 amino acids. There are two hinge regions; between repeats 15-16 and 23-24. Filamin gets cleaved at these hinge regions to generate smaller fragments of the protein. Filamin has two actin-binding sites with a V-linkage between them, so that it cross-links actin filaments into a network with the filaments orientated almost at right angles to one another"
    Filamin proteins include:
    Over-expression of FLNA stops the regeneration of bladder carcinoma (BC) cells, by inhibiting the cell cycle and inducing apoptosis of BC cells.[3] FLNA has also been shown to reduce the mobility and invasion abilities of BC cells."
    Nothing about AD and being "a scaffolding protein, in the brain."
  • E
    8/21/20 9:14 am EST: AC Immune upcoming readout risk-reward skews positive, says SVB Leerink 09:14 ACIU SVB Leerink analyst Marc Goodman maintained an Outperform rating and $13 price target on AC Immune ahead of the upcoming data readout for the company's semorinemab Phase 2 study, TAURIEL, in treating prodromal-to-mild Alzheimer's disease in the second half of 2020. The analyst likes the risk/reward of the readout, as he expects limited downside of around 10% with a negative trial, but a 45%-50% move upward with a positive trial.

    Read more at:
    AC Immune upcoming readout risk-reward skews positive, says SVB Leerink SVB Leerink ACIU
    AC Immune upcoming readout risk-reward skews positive, says SVB Leerink SVB Leerink ACIU
  • E
    AC Immune Says Phase 2 Study of Alzheimer's Drug Fails to Meet Primary Endpoint, Stock Drops Pre-Bell
    23 Sep 2020 08:56 HE
    08:56 AM EDT, 09/23/2020 (MT Newswires) -- AC Immune (ACIU) said Wednesday a phase 2 study conducted by its joint venture partner Genentech on its proprietary antibody semorinemab in early Alzheimer's disease failed to meet the primary endpoint.

    The company said that semorinemab was not able to reduce the decline on the Clinical Dementia Rating-Sum of Boxes, a scale used to characterize Alzheimer disease and related dementias. Secondary endpoints using scales that measure cognitive ability and the competence of patients in daily living activities were also not met.

    An evaluation of semorinemab for moderate Alzheimer's disease in a phase 2 study is currently underway, the company said.

    Shares dropped 42.7% in pre-market trading.